TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Health & Fitness

    Neurology Minute

    The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.

    Advertise

    Copyright: © 2019

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis Aug 12, 2026
    Show notes

    Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis.

    Show citation:

    Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2

    Negative Myoclonus Aug 11, 2026
    Show notes

    Dr. Zohaib Siddiqi shares clinical pearls on negative myoclonus.

    An Update on Troriluzole Aug 10, 2026
    Show notes

    Dr. Margarita Fedorova discusses the use of troriluzole for spinocerebellar ataxia.

    Show citations:

    https://www.neurology.org/doi/10.1212/WNL.0000000000209018

    https://clinicaltrials.gov/study/NCT06034886

    https://clinicaltrials.gov/study/NCT02960893

    The Current State of Diagnostics for Neuroimmunologic Disorders in Africa Aug 07, 2026
    Show notes

    Drs. Paul Crane, Fiifi Duodu, and Malya Sahu discuss neuroimmunology and multiple sclerosis diagnosis in Africa, including challenges and efforts to improve care.

    Show citation:

    Sahu M, Chomba M, Duodu F, Diaz MM, Sokhi D, Saylor D. The Current State of Diagnostics for Neuroimmunological Disorders in Africa. J Cent Nerv Syst Dis. 2025;17:11795735251385319. Published 2025 Nov 19. doi:10.1177/11795735251385319

    Ampreloxetine for Neurogenic Orthostatic Hypotension in MSA Aug 06, 2026
    Show notes

    Dr. Elizabeth Coon and Dr. Lucy Norcliffe-Kaufmann discuss the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions.

    Show citation:

    Freeman R, Kaufmann H, Biaggioni I, et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology. 2026;107(3):e218284. doi:10.1212/WNL.0000000000218284

    Sex Differences in Levodopa Pharmacokinetics in Early Parkinson Disease Aug 05, 2026
    Show notes

    Dr. Margarita Fedorova explores sex-related differences in the pharmacokinetics of levodopa among levodopa-naïve patients with PD and evaluates their relationships with levodopa-related complications.

    Show citation:

    Conti V, De Bellis E, Corbi G, et al. Sex differences in levodopa pharmacokinetics in early Parkinson's disease: implications on levodopa-related complications. Front Pharmacol. 2026;17:1748932. Published 2026 Apr 7. doi:10.3389/fphar.2026.1748932

    Psychiatric Comorbidities in Epilepsy - Part 2 Aug 04, 2026
    Show notes

    In part two of this series, Dr. Halley Alexander and Dr. Heidi Munger Clary discuss the steps to take if you are screening for a psychiatric comorbidity and the results indicate that someone may be positive for depression, anxiety, or another condition.

    Show citations:

    Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334. doi:10.1111/epi.17140

    Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. Neurology. 2018;91(18):829-836. doi:10.1212/WNL.0000000000006425

    August 2026 President Spotlight: How We're Working with the AMA Aug 03, 2026
    Show notes

    In the August episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost highlight how the AAN's growing representation within the AMA strengthens the voice of neurology.

    Stay informed by watching the President's Spotlight video.

    Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 2 Jul 31, 2026
    Show notes

    In part two of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the FENhance 1 and 2 trials looking at fenebrutinib in relapsing MS.

    For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting.

    Read more about the Fenebrutinib Trial.

    Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 1 Jul 30, 2026
    Show notes

    In part one of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the fenebrutinib trial and highlight the key takeaways that healthcare providers should be aware of.

    For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting.

    Read more about the Fenebrutinib Trial.

    Previous 1 4 5 6 7 8 205 Next

    Related Podcasts

    Fresh Air

    1

    Fresh Air Arts
    Twenty Thousand Hertz

    2

    Twenty Thousand Hertz Arts
    The Black Tapes

    3

    The Black Tapes Arts
    Snap Judgment

    4

    Snap Judgment Arts
    Here’s The Thing with Alec Baldwin

    5

    Here’s The Thing with Alec Baldwin Arts
    The NoSleep Podcast – Creative Reason Media Inc.

    6

    The NoSleep Podcast – Creative Reason Media Inc. Arts
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights